ANVS

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −22%

below

Price vs 50-day avg +2%

above

RSI (14) 58

neutral

MACD trend Positive

52-week position 11%

near low

Momentum

relative strength

Weak

1-month return +11%

trailing

6-month return −36%

trailing

YTD return −42%

this year

Relative strength −44%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $2 › 200d $3 — 200d above 50d

Institutional flow Distributing

2 of 58 funds reported for Jun 30 · net -1.0K sh shares

Insider flow Accumulating

Net +$142.8K over 90 days · 0% sells

Short interest Falling

13.87% of float · ▼ -4.3% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

58 holders — near 3-yr high, broad support

Squeeze score 83

high risk · 0–100

Fundamentals

Excellent

EPS growth +39%

Y/Y

Balance sheet $19.5M

net cash

Quant / Vol

risk profile

Very High

Volatility 92%

annualized · 1-yr

Max drawdown −69%

past year

ATR 7.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 15, 2026

Technicals

trend & momentum for long-term holders Neutral

2 · 2 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−22% Bearish

Price vs 50-day avg

+2% Bullish

RSI (14)

58 Neutral

MACD trend

Positive Bullish

52-week position

11% Bearish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $2 › 200d $3 — 200d above 50d

Institutional flow Distributing

2 of 58 funds reported for Jun 30 · net -1.0K sh shares

Insider flow Accumulating

Net +$142.8K over 90 days · 0% sells

Short interest Falling

13.87% of float · ▼ -4.3% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

58 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $2 Now $2 · 11% 52-wk high $6

vs 200-day avg -22% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
PD open-label extension (OLE) study enrollment	40%	Q1 2026	—
Phase 3 AD trial enrollment	85%	Q1 2026	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ANVS Annovis Bio, Inc. this stock	$68.95M	-42.5%	—	—	13.9%
ONC BeOne Medicines Ltd.	$436.30B	-0.6%	+22179.2%	887.9	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$126.50B	+9.9%	+46.2%	29.6	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.50B	-14.0%	+20.8%	16.2	3.2%
ARGX Argenx SE	$57.20B	+8.8%	—	—	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 15.1%
Reported: 2 of 58
Top holder: MARSHALL WACE, LLP

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

4.8M

Days to cover: 4.0d
Change: -216.4K sh

View

Short Volume

Short vol %

66%

As of: Jul 8, 2026

Short Total

View

Fails to Deliver

FTD shares

6.0K

Value: $11.0K
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

84.4%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$142.8K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-28.9M
EPS diluted: $-1.40

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 17, 2026
This year: 11

View

Proposed Sales

Value

$14.8K

Shares: 7.1K
Filed: Apr 2, 2026

View

Exempt Offerings

Offering

$1.1M

Filed: Apr 25, 2023

View

Earnings & Events

Earnings Calls

Last call

Aug 12, 2025

View

Performance

	5D	20D	120D	MTD	YTD
ANVS	+7.0%	+11.2%	-36.2%	+7.0%	-42.5%
SPY	-0.2%	+0.8%	+7.4%	-0.2%	+9.3%
vs SPY	+7.2%	+10.3%	-43.7%	+7.2%	-51.8%

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance